EARLY MANAGEMENT AND PREVENTION OF SEPSIS AND SEPSIS-LIKE SYNDROMES

The present invention relates to compositions and methods of treating sepsis, acute inflammatory syndromes such as systemic inflammatory response syndrome (SIRS), anthrax and severe acute respiratory syndrome coronavirus (SARS and SARS- CoV2), neo-natal acute respiratory distress syndrome (neo-natal ARDS) by PLA2 and/or metalloprotease inhibitors, in particular, in combination with antibiotics. In embodiments, the PLA2 inhibitor is varespladib, methyl varespladib, AZD2716- R,S and LY433771, the metalloprotease inhibitor is Prinomastat, Batimastat, marimastat or vorinostat..

Medienart:

Patent

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Europäisches Patentamt - (2021) vom: 22. Apr. Zur Gesamtaufnahme - year:2021

Sprache:

Englisch

Beteiligte Personen:

LEWIN MATTHEW R [VerfasserIn]
CARTER REBECCA [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2021-04-22, Last update posted on www.tib.eu: 2023-11-23, Last updated: 2023-12-01

Patentnummer:

WO2021076712

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA011315555